Nivolumab plus ipilimumab approved in the EU for Mismatch Repair Deficient or Microsatellite Instability–High (MSI-H) metastatic colorectal cancer after prior chemotherapy

Approval was based on the Phase 2 CheckMate -142 trial in patients who received prior treatment with fluoropyridine, oxaliplatin and irinotecan, which found that 64.7% of patients had a durable response, and 12.6% achieved a complete response.

Source:

Biospace Inc.